Xenon's CEO on Kv7 potassium channel modulation in the CNS space and his thoughts on NaV1.7/1.8 for pain

blonca9
May 14, 2024
1 min read

Ian Mortimer gives the rationale for Kv7 in epilepsy and major depressive disorder, and explains why Xenon has chosen the NaV1.7 sodium channel in the pain space.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Xenon's CEO on Kv7 potassium channel modulation in the CNS space and his thoughts on NaV1.7/1.8 for pain

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight